drugset / Trial / NCT00002429

Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen

NCT00002429

Phase 3 Completed 500 enrolled Bristol-Myers Squibb
Parallel-groupTreatment

Summary

This study tests a new form of didanosine, ddI EC, a coated pill that passes through the stomach before dissolving. The purpose of this study is to compare the effectiveness of an anti-HIV drug combination that includes ddI EC versus another anti-HIV drug combination.

Timeline

Start
1999-07
Primary completion
2001-01
Completion
2001-01

Publications

  • Background Gathe J, Badero R, Grimwood A, Abrams L, Klesczewski K, Mclaren C. AI454152: Comparison of a Triple Combination Regimen Containing an Enteric Coated Formulation of Didanosine Administered Once-Daily Versus a Regimen of Combivir Plus Nelfinavir. 8th Conference on Retroviruses and Opportunistic Infections, 2001 Feb 4-8. (abstract no 319)

Drugs

EvaluationDrugModalityDoseRoute
Subject Didanosine Small molecule
Subject Lamivudine/Zidovudine Unknown
Subject Stavudine Other / unclassified
Background Nelfinavir Other / unclassified